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Abstract:  Dyslipidaemia is frequently present in obesity, metabolic syndrome (MetS) and type 2 diabetes mellitus 
(T2DM). The predominant features of dyslipidaemia in these disorders include increased flux of free fatty acids (FFA), 
raised triglyceride (TG) and low high density lipoprotein cholesterol (HDL-C) levels, a predominance of small, dense (a-
therogenic) low density lipoprotein cholesterol (LDL) particles and raised apolipoprotein (apo) B values Posprandial hy-
perlipidaemia may also be present. Insulin resistance (IR) appears to play an important role in the pathogenesis of dyslipi-
daemia in obesity, MetS and T2DM. The cornerstone of treatment of this IR-related dyslipidaemia is lifestyle changes and 
in diabetic patients, tight glycaemic control. In addition to these measures, recent clinical trials showed benefit with statin 
treatment. Nevertheless, a substantial percentage of patients treated with statins still experience vascular events. This re-
sidual vascular risk needs to be addressed. This review summarizes the effects of hypolipidaemic drug combinations (in-
cluding statins with cholesterol ester protein inhibitors, niacin, fibrates or fish oil, as well as fibrate-ezetimibe combina-
tion) on the residual vascular risk in patients with obesity, MetS or T2DM. 
Keywords: Dyslipidaemia, obesity, metabolic syndrome, type 2 diabetes mellitus, residual vascular risk. 
INTRODUCTION 
  Dyslipidaemia is an important modifiable vascular risk 
factor [1, 2]. Elevated low density lipoprotein cholesterol 
(LDL-C) levels are the major target in the management of 
dyslipidaemia and statins are the most widely used hypolipi-
daemic agents for cardiovascular disease (CVD) prevention. 
However, the gains from CVD prevention over the last 4 
decades are being challenged by a global epidemic of obe-
sity, metabolic syndrome (MetS) and type 2 diabetes melli-
tus (T2DM) [3]. Recent epidemiological data from the USA 
[4] and UK [5] show an unfavourable trend in CVD mortal-
ity in younger men and women (35 to 44 years), related to 
the obesity, MetS and T2DM epidemic. In these age groups, 
CVD mortality increased significantly for the first time in 
over 2 decades [4, 5]. Visceral adiposity, a marker of 
“dysfunctional adipose tissue”, plays a key role in the devel-
opment of the MetS and T2DM. It is characterised by accu-
mulation of fat in the central part of the body and correlates 
with insulin resistance (IR) [6]. Visceral adipocytes are 
large, insulin-resistant and highly active metabolically. 
Through the production of a variety of adipokines, adipo-
cytes play a role in the pathogenesis of inflammation, 
dyslipidaemia and hypertension [7]. The co-existence of 
these risk factors increases the CVD morbidity and mortality  
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associated with obesity, MetS and T2DM [8]. In these disor-
ders, the phenotype of dyslipidaemia is highly atherogenic. It 
usually manifests as the so-called “atherogenic lipid triad” 
consisting of elevated serum triglyceride (TG) levels, in-
creased levels of small-dense LDL (sdLDL) particles and 
decreased levels of high density lipoprotein cholesterol 
(HDL-C) [9, 10]. 
  We review the pathophysiology and treatment of dyslipi-
daemia associated with obesity, MetS and T2DM, focusing 
on strategies aiming at reducing the residual CVD risk [11] 
after statin treatment to LDL-C goal. 
PATHOPHYSIOLOGY OF DYSLIPIDAEMIA ASSO-
CIATED WITH OBESITY, METS AND T2DM 
  Patients with obesity, MetS or T2DM show specific lipid 
abnormalities that promote atherosclerosis and contribute to 
the residual CVD risk observed in these patients after LDL-
C reduction to treatment goals with statins and optimum 
treatment of comorbidities [11-14]. 
A. The Atherogenic Lipid Triad  
  In most cases, dyslipidaemia in patients with obesity, 
MetS and T2DM is characterized by (a) increased flux of 
free fatty acids (FFA), (b) raised TG values, (c) low HDL-C 
values, (d) increased small, dense LDL particles, and (e) 
raised apolipoprotein (apo) B levels [15, 16]. 
  IR appears to play an important role in the pathogenesis 
of this type of dyslipidaemia [17]. IR is associated with en-
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cation leading to an increased flux of FFA into non-adipose 
tissues, including the liver and muscle [17, 18]. Since FFA 
compete with glucose for cellular uptake and metabolism, 
they can further reduce insulin sensitivity, instituting a vi-
cious cycle [19, 20]. 
  Adipose tissue, through the secretion of adipokines [7], 
plays a central role in whole body homeostasis including 
food intake, regulation of energy balance, insulin action, 
lipid and glucose metabolism, angiogenesis and vascular 
remodelling, regulation of blood pressure (BP) and coagula-
tion [21]. Excessive visceral adiposity increases the avail-
ability of FFA through the hydrolysis of adipocyte TG by a 
variety of lipases, including triglyceride lipase, lipoprotein 
lipase (LpL), hormone-sensitive lipase and endothelial lipase 
[22, 23]. Such increases in circulating FFA lead to TG ac-
cumulation in muscle and liver (fatty liver) and raise circu-
lating TG levels due to enhanced hepatic production of very 
low density lipoprotein (VLDL) cholesterol [22, 24]. Excess 
VLDL secretion increases the flux of FFA and TG to muscle 
and other tissues, further inducing IR. When influx of FFA 
to the liver exceeds efflux, there is increased hepatic FFA 
uptake, synthesis and secretion that can lead to hepatic stea-
tosis, which in turn exacerbates IR [25, 26], giving rise to a 
new vicious cycle. In addition, overloading of the white adi-
pose tissue (WAT) beyond its storage capacity can also ad-
versely affect skeletal and cardiac muscle, liver as well as 
pancreatic function [27]. 
  Cholesteryl ester transfer protein (CETP) is secreted by 
the adipose tissue and is an important determinant of lipo-
protein composition because it mediates the transfer of cho-
lesteryl esters (CE) from CE-rich lipoproteins to TG-rich 
lipoproteins in exchange for TG [28]. In obese patients, 
CETP activity and mass are increased [29]. This contributes 
to the increased flux of FFA but also to the rise in circulating 
TG levels. However, increased flux of FFA from the periph-
ery to the liver in IR states stimulates hepatic TG synthesis, 
which in turn promotes the production of VLDL and apoB 
[16, 29]. Several studies showed that hepatic apoB secretion 
is metabolically regulated [15]. The apoB gene is constitu-
tively expressed and in most cases the modulation of apoB 
production does not involve changes in apoB mRNA levels 
[15]. These observations suggest that post-translational 
mechanisms play a role in the regulation of apoB levels, in-
cluding endoplasmic reticulum translocation and protein 
degradation. Thus, reduced apoB degradation might be the 
main contributor to the increase in plasma apoB levels [17, 
30]. On the other hand, hepatic IR can lead to increased 
availability of apoB and might predispose to higher rates of 
hepatic VLDL assembly and secretion, the key steps in the 
development of metabolic dyslipidaemia [25]. In lean sub-
jects, all these factors would stimulate adiponectin produc-
tion from the WAT [7, 21]. Adiponectin reduces hepatic TG 
production and increases insulin sensitivity [7, 31]. How-
ever, this compensatory mechanism is blunted in obesity, 
because adiponectin levels are low and do not increase under 
physiological stimuli [7, 21]. 
  In IR, circulating HDL-C levels are also decreased and 
this appears to be linked to the overproduction of TG-rich 
lipoproteins. Low HDL-C levels represent an independent 
risk factor for CVD [32-34]. Even though the mechanisms 
are not entirely clear, the enrichment of HDL particles with 
TG appears to be implicated, leading to HDL particle insta-
bility and degradation. CETP plays an important role in lipid 
exchange between TG-rich lipoproteins and HDL [35, 36]. 
In the presence of raised plasma TG levels, CETP mediates 
the exchange of TG (from VLDL) for CEs (from HDL), re-
sulting in HDL particles enriched in TG and depleted of CE, 
which are prone to degradation [37]. These TG-rich but cho-
lesterol-depleted HDL particles undergo hydrolysis of their 
TG component by hepatic lipase (HL), which plays an im-
portant role in the enhanced catabolism of HDL in IR states 
[38]. ApoA, the main protein of HDL, is then dissociated 
from HDL particles [39]. Coupled with increased catabolic 
rate, these changes result in reduced and TG-rich HDL parti-
cles, which cannot carry out reverse cholesterol transport 
effectively [40]. Another possibility is that the altered (due to 
IR) lipid flux in the liver may reduce the hepatic production 
of apoA [41]. Thus, both depletion of HDL particles from 
CE by CETP and alterations in apoA might contribute to the 
reduction in HDL-C mass and HDL particle size (HDL-3) 
[37-41]. It was shown that as the number of MetS compo-
nents increases, the HDL phenotype shifts to a greater per-
centage of small HDL-3 and less large HDL-2 particles, re-
sulting in a decreased HDL-2/HDL-3 ratio [42]. In addition, 
HDL-2 levels and the HDL-2/HDL-3 ratio independently 
correlated with HDL-C (positively) and TG levels (nega-
tively). HDL-3 concentration positively correlated with 
HDL-C and TG levels. This phenomenon may contribute to 
an impaired reverse cholesterol transport and to attenuated 
antiatherogenic activity of HDL in MetS [42]. 
  Patients with IR have normal or slightly elevated LDL-C 
levels but significantly higher concentrations of the athero-
genic sdLDL subfractions [43-45]. Hypertriglyceridaemia is 
implicated in the increased presence of sdLDL particles in 
IR. In hypertriglyceridaemic states, large TG-rich VLDL 
(VLDL1) molecules accumulate [43]. When VLDL1 is 
lipolysed by LpL, a population of LDL particles with 
changed apoB conformation is produced. These particles fail 
to bind efficiently to LDL receptors and have a prolonged 
residence time in the circulation. Through the action of 
CETP, CEs are replaced by TG in LDL and HDL particles 
[43]. HL also acts on TG-rich LDL to generate sdLDL, 
which is associated with higher vascular risk [46, 47]. This is 
because sdLDL particles have reduced LDL receptor-
mediated clearance, increased retention in the arterial wall, 
increased susceptibility to oxidation and are enriched in 
apoB [44, 48]. It was shown that higher apoB levels predict 
CVD better than the absolute LDL-C levels [49] and are the 
most prevalent lipid disorder in patients with premature 
coronary artery disease (CAD) [50]. Interestingly, both 
sdLDL and the sdLDL-C/LDL-C ratio are inversely related 
with adiponectin levels [51]. Thus, hypoadiponectinaemia 
may provide a useful index for qualitative changes in LDL 
particles in IR states, especially when combined with the 
measurement of apoB levels [15]. 
B. Postprandial Lipaemia  
  Postprandial lipaemia refers to the state of lipid metabo-
lism between food intake and the post-absorptive state. Fast-
ing hypertriglyceridaemia is an independent risk factor for 
CVD [52, 53]. Moreover, TG levels are predictive of subse-
quent CVD events in statin-untreated high-risk patients and 
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lower vascular risk [54]. This beneficial effect of statins was 
more pronounced in patients with MetS or T2DM [54]. On 
the other hand, postprandial hyperlipidaemia (mainly post-
prandial hypertriglyceridaemia) is frequently present in pa-
tients with premature CVD [55]. It was suggested that fast-
ing plasma TG concentrations are the best predictor of post-
prandial lipaemia [56, 57]. However, postprandial lipaemia 
occurs even in subjects who are normolipidaemic in the fast-
ing state [58, 59]. 
  Since postprandial hyperlipidaemia is relatively common 
in IR states [60, 61], it is probable that the clearance of both 
chylomicrons and VLDL from the circulation is impaired in 
these patients. In IR, the antilipolytic effect of insulin in adi-
pose tissue is attenuated [62]. This might contribute to the 
postprandial increase in FFA levels [15]. The mechanisms 
underlying postprandial hyperlipidaemia also include a mod-
est reduction in LpL and HL activity, increased production 
and higher plasma levels of apoC-III (an inhibitor of LpL) 
and the defective suppression of hepatic VLDL secretion 
postprandially [63-65]. Because VLDL and chylomicrons 
compete for the same LpL- and receptor-mediated TG-
removing pathways, nonsuppressed VLDL secretion reduces 
the clearance of chylomicrons and their remnants. Post-
prandial hyperlipidaemia also promotes the formation of 
atherogenic LDL and HDL particles in a way similar to fast-
ing hypertriglyceridaemia, as described above [60]. 
TREATMENT 
A. Weight Loss 
  Obesity is an important vascular risk factor [1, 66]. 
Weight loss with lifestyle measures (diet and exercise) re-
mains the first priority in IR patients in order to control 
dyslipidaemia and prevent T2DM, but is difficult to achieve 
and maintain [67, 68]. Therefore, drugs that facilitate weight 
loss might prove useful. Modest weight loss (>5%) with ei-
ther sibutramine or orlistat appears to be associated with a 
reduction in TG levels and with favourable changes in adi-
pokines, including an increase in serum adiponectin and a 
decrease in serum resistin levels [69, 70]. In obese T2DM 
patients with MetS, orlistat plus diet improved several vascu-
lar risk factors including fasting glucose, HbA1c, total cho-
lesterol and LDL-C levels, systolic BP, waist circumference 
and homeostasis model assessment index (HOMA) com-
pared with diet and exercise alone [71]. Similar were the 
findings in the XENical in the prevention of Diabetes in 
Obese Subjects (XENDOS) Trial [72] in obese subjects 
without T2DM, in patients with T2DM on oral hypoglycae-
mic drugs [73] and in patients with T2DM on insulin [74]. 
Thus, the combination of weight loss with the beneficial ef-
fects on adipokine levels during orlistat treatment might pro-
vide additional clinical benefits in obese patients with 
T2DM.  
  Young morbidly obese patients (body mass index (BMI) 
> 40 kg/m
2 or BMI > 35 kg/m
2 in the presence of significant 
comorbidities) have an estimated 22% reduction in expected 
remaining lifespan, representing an approximate loss of 12 
years of life [75]. In these patients, bariatric surgery is an 
effective treatment [76]. Bariatric surgery results in signifi-
cant weight loss (approximately 50-70% of excessive body 
weight), has a 70% long-term success rate and improves as-
sociated comorbidities (hypertension, dyslipidaemia, T2DM 
and obstructive sleep apnea) [77-79]. The beneficial effects 
of bariatric surgery on adipokine levels might play a role in 
the observed weight loss [80-82]. 
B. Drug Treatment 
1. Statin Treatment 
  As mentioned above, IR-associated dyslipidaemia is 
characterized by elevated TG and low HDL-C levels and a 
preponderance of sdLDL particles, while LDL-C levels are 
similar to subjects without IR. The cornerstone of treatment 
for IR-related dyslipidaemia is lifestyle changes and in dia-
betic patients, tight glycaemic control. In addition to these 
measures, recent clinical trials demonstrated the benefits of 
statin treatment [83]. In the Collaborative Atorvastatin Dia-
betes Study (CARDS), atorvastatin (10 mg/day) reduced 
vascular events, including stroke, in patients with T2DM 
without high LDL-C [3.1 mmol/l (120 mg/dl)] and without 
CVD at baseline [84]. In post hoc analyses of the GREek 
Atorvastatin and Coronary heart disease Evaluation 
(GREACE) study, we showed that patients with CAD and 
MetS [85] or T2DM [86] benefit from statin treatment more 
than those without MetS or T2DM. Statin treatment (mainly 
atorvastatin) substantially reduced total mortality and CVD 
events by nearly one-half compared with untreated patients 
within a 3-year follow-up period. The Heart Protection Study 
(HPS) [87] showed a reduction in CVD events in patients 
with T2DM with or without CVD with simvastatin (40 
mg/day). The Treating to New Targets (TNT) study also 
showed that patients with CAD and MetS [88] or T2DM [89] 
are at higher risk compared with patients without MetS or 
T2DM. Moreover, these 2 prespecified analyses of the TNT 
study showed that patients with CAD and MetS or T2DM 
benefit from aggressive LDL-C lowering with atorvastatin 
more than CAD patients without MetS of T2DM [88, 89]. 
Furthermore, a recent meta-analysis of 14 randomized statin 
trials including 18, 686 patients with T2DM showed a 21% 
reduction in major vascular events and 13% reduction in 
vascular mortality for every 1 mmol/l (37 mg/dl) reduction 
in LDL-C levels [90]. In the Justification for the Use of Stat-
ins in Prevention: an Intervention Trial Evaluating Rosuvas-
tatin (JUPITER) trial, 7, 375 participants (41.4% of the study 
population) had MetS without T2DM [91]. Patients enrolled 
in the JUPITER trial had LDL-C levels < 130 mg/dl (3.4 
mmol/l) and no T2DM or established vascular disease but 
had elevated high sensitivity C-reactive protein (hsCRP) 
levels ( 2 mg/l) [91]. Those treated with 20 mg of rosuvas-
tatin had significant reductions in vascular morbidity and 
mortality and in total mortality after a median follow-up of 
1.9 years [91]. In JUPITER, rosuvastatin significantly re-
duced the risk for the primary end-point (myocardial infarc-
tion, stroke, arterial revascularization, hospitalization for 
unstable angina, vascular death) in both patients with and 
without MetS, with no evidence of heterogeneity between 
these subgroups (p for interaction = 0.14) [91]. JUPITER is 
the first study that showed a reduction in vascular events 
with statin treatment in patients with MetS but without estab-
lished vascular disease or T2DM [91].  
  Nevertheless, even after the statin-induced reductions in 
CVD morbidity and mortality in the above studies it is obvi-
ous that a substantial percentage of patients still have a vas-
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that needs to be targeted [92]. Therefore, it might be useful 
to combine statins with other lipid-lowering agents to man-
age residual CVD risk. These agents might include a fibrate, 
niacin, fish oil or (possibly in the future) CETP inhibitors 
[93]. This is supported by the findings of an analysis of the 
Get With The Guidelines database (136, 905 patients hospi-
talized with CAD from 2000 to 2006). Almost half of the 
patients had admission LDL-C levels < 2.6 mmol/l (100 
mg/dl) but more than half had admission HDL-C levels < 1.0 
mmol/l (40 mg/dl). Less than 10% had HDL-C levels  1.5 
mmol/l (60 mg/dl) [94]. These findings suggest that target 
LDL-C goals should be lower and that effective treatments 
to raise HDL-C should be used or developed [95]. In A 
Study to Evaluate the Effect of Rosuvastatin on Intravascular 
Ultrasound-Derived Coronary Atheroma Burden [ASTER-
OID]), rosuvastatin 40 mg/day achieved an average LDL-C 
concentration of 1.6 mmol/l (60.8 mg/dl) and increased 
HDL-C by 14.7%, resulting in significant regression of 
coronary atherosclerosis assessed with intravascular ultra-
sound (IVUS) [96]. A meta-analysis of IVUS trials showed 
that statin treatment is associated with regression of coronary 
atherosclerosis when LDL-C levels are substantially reduced 
and HDL-C levels are increased by more than 7.5% [97]. 
These findings suggest that statin benefits result from both 
the reduction in LDL-C levels and the increase in HDL-C. In 
the GREACE study, the statin-induced HDL-C increase was 
independently associated with lower CVD event rates [32, 
98]. This suggests that the vascular risk reduction associated 
with HDL-C rise is significant even during aggressive LDL-
C-lowering treatment (46% mean reduction in LDL-C lev-
els) [32, 98]. Interestingly, rosuvastatin increased HDL-C 
levels by increasing the cholesterol mass only in the larger 
HDL particles in a dose-dependent manner, suggesting a 
more effective reverse cholesterol transport [99]. Atorvas-
tatin also reduced all LDL subclasses, resulting in a signifi-
cant reduction in LDL particle number and in an increase in 
LDL particle size [100]. In addition, HDL particle size in-
creased [100]. Statins also have beneficial effects on post-
prandial lipaemia [101]. 
  Statin-induced HDL-C increase is also related to a sig-
nificant improvement in renal function [102]. High-risk pa-
tients with dyslipidaemia show a decline in renal function 
over time, which further increases the risk for vascular 
events [85, 103-106]. Statin treatment improved renal func-
tion and the statin-induced HDL-C increase appears to con-
tribute to this effect [106]. Improved reverse cholesterol 
transport or other “pleiotropic” actions of HDL particles 
might play a role in the beneficial effects of HDL-C on renal 
function [102]. In addition, this improvement in renal func-
tion is independently associated with a reduction in vascular 
events [85, 103-106]. These finding support the concept that 
improving lipid variables other than LDL-C also benefit re-
nal function. 
2. Statin Combined with Novel Agents for Raising HDL-C 
  After attaining the LDL-C goals, the most promising 
lipid risk factor to target seems to be HDL-C. The effects of 
statins on HDL-C levels depend on the compound, dose and 
lipid phenotype [107]. Statins do not appear to be the most 
appropriate hypolipidaemic agents to increase HDL-C levels 
[96]. In this respect, novel agents (which might be available 
in the near future) including apo-I (Milano), anti CETP vac-
cine (CETi-1) and CETP inhibitors (anacetrapib or JTT-
705), might prove to be useful. The most promising regimen 
appears to be CETP inhibition combined with a statin [95, 
108]. A recent publication suggests that anacetrapib (which 
is well tolerated and had no effect on BP), as monotherapy or 
co-administered with atorvastatin, significantly lowered 
LDL-C and increased HDL-C levels [108]. The net result of 
treatment with anacetrapib + atorvastatin was 70% lower-
ing of LDL-C and more than doubling of HDL-C levels 
[108]. In contrast, torcetrapib (a CETP inhibitor whose de-
velopment was halted because of increased mortality) raised 
BP independently of CETP inhibition [109, 110]. An in-
crease in circulating aldosterone levels appears to contribute 
to this BP rise with torcetrapib [110]. It appears that this ad-
verse action is not a drug class effect but compound-specific. 
Anacetrapib was associated with a dose-dependent lipopro-
tein a [Lp(a)] lowering, with up to 50% reduction at the 
highest doses [108]. It remains to be established whether 
these effects of anacetrapib on lipid parameters will translate 
into clinical benefit. 
3. Statin-Niacin Combination Treatment 
  In the HDL-Atherosclerosis Treatment Study (HATS) 
[111] and the Arterial Biology for the Investigation of the 
Treatment Effects of Reducing Cholesterol 3 (ARBITER 3) 
study [112], niacin-statin combination vs statin alone re-
sulted in greater reduction in carotid intima-media thickness 
(cIMT) in patients with CAD, T2DM and/or MetS. Combin-
ing niacin with statins to optimize the lipid profile [lower TG 
levels below 1.7 mmol/l (150 levels mg/dl) and non-HDL-C 
levels below 3.4 mmol/l (130 mg/dl)] might be useful in 
T2DM. However, higher doses of niacin can impair glycae-
mic control [67]. Therefore, niacin therapy should be insti-
tuted only in patients with well-controlled diabetes and glu-
cose levels should be monitored. In patients with T2DM but 
without CAD, it is recommended to achieve LDL-C levels 
below 2.6 mmol/l (100 mg/dl) whereas in patients with 
T2DM and CAD the goal is to achieve LDL-C levels below 
1.8 mmol/l (70 mg/dl) [113]. In both groups, non-HDL-C 
levels should be < 3.4mmol/l (130 mg/dl) and < 2.6 mmol/l 
(100 mg/dl), respectively [113]. In diabetic patients, it is also 
desirable to achieve TG levels < 1.7 mmol/l (150 mg/dl) and 
HDL-C levels > 1.0 mmol/l (40 mg/dl) and > 1.3 mmol/l (50 
mg/dl) in men and women, respectively [114]. Niacin-statin 
combination therapy could possibly help achieve these addi-
tional goals; however, there is no clear evidence that this 
combination will reduce vascular events more than statins 
alone in diabetic patients [67]. 
4. Statin-Fibrate Combination Treatment 
  Mounting evidence suggests that TG play a role in the 
pathogenesis of atherothrombosis [115]. Recent post hoc 
analyses of statin trials suggest that lowering TG levels is 
associated with a reduction in vascular events [54, 116]. 
Statin-induced TG lowering may translate in clinical benefit 
both in patients with acute coronary syndromes and stable 
CAD, beyond LDL-C lowering to < 1.8 mmol/l (70 mg/dl) 
or < 2.6 mmol/l (100 mg/dl), respectively [54, 116]. 
  The main effect of fibrates is a decrease in TG levels (by 
about 20-30% in major outcomes studies [117-121], al-
though larger reductions may be seen in patients with above 
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reduction in postprandial TG levels and remnant lipoprotein 
particles, especially in patients with T2DM or MetS [122, 
123-126]. Fibrates also raise HDL-C (by 5-10%) by stimu-
lating apoA-I and apoA-II expression [123, 127]. Fenofibrate 
also lowers LDL-C, more so in patients with average than in 
those with high baseline TG levels [117, 128]. A study using 
nuclear magnetic resonance (NMR) analysis showed that 
fenofibrate lowered TG levels by 58% and increased HDL-C 
levels by 18% [129]. NMR analysis revealed that VLDL, 
particularly large VLDL, intermediate density lipoprotein 
(IDL) and sdLDL were also significantly decreased and LDL 
distribution was shifted towards larger particles. HDL distri-
bution was also altered; there was an increase in small HDL 
and a decrease in large HDL particles, resulting in a signifi-
cant decrease in HDL particle size, from 9.1 to 8.9 nm, as 
well as a 27% increase in HDL particle number. Among in-
flammation markers, hsCRP was significantly decreased by 
42% [129]. Moreover, fenofibrate also lowers apoCIII levels 
[130-132] and exerts anti-inflammatory actions [123, 129, 
133]. 
  The Fenofibrate Intervention and Even Lowering in Dia-
betes (FIELD) study evaluated the effect of treatment with 
fenofibrate 200 mg/day in reducing macrovascular and mi-
crovascular complications in 9, 795 patients with T2DM 
[134]. At the end of the 5-year follow-up period, treatment 
with fenofibrate was associated with a nonsignificant 11% 
reduction in relative risk for the primary end point. There 
was, however, a significant 11% relative reduction in risk for 
the secondary end point of total cardiovascular events, ex-
cluding unstable angina, and this was largely driven by sig-
nificant reduction in risk for nonfatal MI and coronary and 
all revascularization procedures. Regarding the microvascu-
lar complications of T2DM, fenofibrate significantly de-
creased the need for retinal laser therapy by 30% and re-
duced the progression of albuminuria [134]. Therefore, com-
bining statins with fenofibrate might further reduce vascular 
risk in IR states [135]. However, it should be emphasized 
there is limited evidence to support this recommendation. 
  Long-term statin-fibrate combination in patients with 
familial combined hyperlipidaemia (FCHL) resulted in more 
effective control of multiple lipid parameters including LDL-
C, TG and HDL-C as well as plasma fibrinogen levels, than 
either monotherapy alone, with a similar safety profile [136-
138]. Moreover, statin-fibrate combination increased LDL 
particle size in patients with FCHL [139]. However, statin-
fibrate combinations are not widely used. This might be due 
to safety concerns, particularly for myopathy and rhabdomy-
olysis, which was reported with lovastatin-gemfibrozil com-
bination [140]. However, this increased risk for rhabdomy-
olysis was not confirmed in studies with other statin-fibrate 
combinations [136-139, 141, 142]. Uncontrolled studies sug-
gested that statin-fibrate combination reduces total and CAD 
mortality in patients with FCHL [143]. The combined target-
ing of LDL-C, TG, apoB and fibrinogen, as well as the in-
crease in LDL particle size, HDL-C and apoA-I might play a 
role in these beneficial effects of statin-fibrate combination. 
  The features of dyslipidaemia of IR states are similar to 
those of FCHL [144]. Moreover, metabolic abnormalities, 
such as the predominance of sdLDL particles and increased 
glycation of LDL [145], raise the vascular risk in these pa-
tients. Glycaemic control appears to improve but does not 
normalize these abnormalities [146]. Statin or fibrate mono-
therapy can improve the lipid profile in patients with T2DM; 
however, they affect different aspects of lipoprotein metabo-
lism [147-149]. Hence, it is difficult to normalize all lipid 
abnormalities in patients with T2DM using monotherapy 
with either a statin or a fibrate [114]. In contrast, atorvas-
tatin-fenofibrate combination improved multiple lipid and 
coagulation abnormalities and reduced the estimated CAD 
risk by 80% in patients with T2DM [148]. Therefore, com-
bining statins with fibrates appears to expand the spectrum 
of therapeutic choices and allow the individualization of hy-
polipidaemic treatment in patients with IR. 
  Non-alcoholic fatty liver disease (NAFLD) is a common 
condition (with a prevalence of 10-39% in the general popu-
lation) characterized by significant lipid deposition in the 
hepatocytes in patients without a history of excessive alcohol 
ingestion [150]. It was shown that IR is associated with 
NAFLD [151]. It was suggested that NAFLD might repre-
sent another feature
  of MetS [152] with decreased insulin 
sensitivity
 being the common underlying factor [153]. The 
strong association of NAFLD
 with other features of the MetS 
including obesity, central
  fat distribution, T2DM, dyslipi-
daemia, hypertension and CVD, further supports this hy-
pothesis [154, 155]. Both MetS and NAFLD appear to be 
independent vascular risk factors [156]. A multifactorial ap-
proach reversed both MetS and NAFLD and reduced esti-
mated CAD risk [157, 158]. Atorvastatin-fenofibrate 
combination was more effective than either monotherapy 
[157, 158]. 
5. Statin-Omega 3 Combination Treatment 
  Omega-3 fatty acids [n-3 polyunsaturated fatty acids 
(PUFA)], including the 20-carbon eicosapentaenoic acid 
(EPA) and the 22-carbon docosahexaenoic acid (DHA), 
lower TG levels and atherogenic remnant lipoproteins both 
in patients with or without T2DM [159-161]. In the former, 
n-3 PUFA might raise LDL-C levels but do not affect gly-
caemic control [160]. 
  Until recently, there were only a few data regarding the 
efficacy of n-3 PUFA supplementation in the primary pre-
vention of CVD. Thus, the results of the Japan EPA Lipid 
Intervention Study (JELIS) offer a new insight in the role of 
n-3 PUFA in this setting. In this study, 18, 645 hypercholes-
terolaemic patients were randomly assigned to receive either 
1, 800 mg of EPA daily with statin (EPA group; n = 9, 326) 
or statin only (controls; n = 9, 319) [162]. The primary end-
point was any major coronary event, including sudden car-
diac death, fatal and non-fatal MI, and other non-fatal events 
including unstable angina pectoris, angioplasty, stenting or 
coronary artery bypass grafting (CABG) [162]. After a mean 
follow-up of 4.6 years, a 19% relative reduction in the pri-
mary endpoint was detected in the EPA group (2.8% in the 
EPA group vs 3.5% in the control group; p = 0.011) [162]. 
Even though the JELIS trial was underpowered for analysis 
of subgroups, EPA treatment resulted in a significant 19% 
reduction in major coronary events among patients with a 
history of CAD (secondary prevention subgroup; n=3, 664); 
the primary end-point occurred in 8.7% in the EPA group vs 
10.7% in the control group (p=0.048) [162]. In patients 
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EPA treatment reduced major coronary events by 18%, but 
this was not significant (1.4% in the EPA group vs 1.7% in 
the control group; p = 0.132) [162]. The relationship be-
tween incident CAD, the number of CAD risk factors and 
EPA treatment was also investigated [163]. Compared with 
patients with normal serum TG and HDL-C levels, those 
with abnormal levels had significantly higher CAD hazard 
ratio (HR) (1.71; 95% confidence interval (CI): 1.11-2.64; p 
= 0.014). In this higher risk group, EPA treatment reduced 
CAD risk by 53% (HR: 0.47; 95% CI: 0.23-0.98; p = 0.043) 
[163]. Therefore, the beneficial effects of EPA on top of 
statin treatment were similar in magnitude in both the pri-
mary prevention and the secondary prevention subgroups, 
but were significant only in the latter subgroup probably 
because of a greater number of events [162] 
  It is of interest that, in the JELIS study, the reduced risk 
associated with EPA treatment was confined to non-fatal 
coronary events [162]. No effect of EPA was observed in 
terms of coronary death or sudden cardiac death [162]. These 
findings differ from those in most previous observational 
studies, where fish intake primarily reduced the risk of fatal 
coronary events or sudden cardiac deaths, but not of non-
fatal coronary events [164-166]. It has been speculated that 
the absence of significant effect on cardiac death in JELIS 
might be due to the increased consumption of fish among 
Japanese, which is approximately 900 mg EPA+DHA per 
day [167]. A recent study also showed that EPA supplemen-
tation (1.8 g/day) reduced the progression of cIMT in pa-
tients with T2DM [168]. Thus, it has been suggested that the 
main benefit at lower levels of consumption (e.g. 1 g/day of 
EPA+DHA) might be prevention of ventricular arrhythmia 
and sudden cardiac death [169], whereas at high levels of 
consumption (e.g. 2-4 g/day of EPA+DHA), modest benefits 
for non-fatal coronary events could also begin to occur be-
cause of the other cardioprotective effects of n-3 PUFA 
[170]. The above suggest that when considering adding a 
second agent to statins in patients with combined dyslipi-
daemia, omega-3 fatty acids provide additional lipid im-
provements without increasing the risk for adverse muscle or 
liver effects [171]. 
6. Statin-Ezetimibe Combination Treatment 
  In patients who cannot reach LDL-C target with statin 
monotherapy, adding ezetimibe is a therapeutic option [172]. 
When added to a statin, ezetimibe lowered LDL-C levels by 
approximately 23% [173, 174]. Besides its LDL-C lowering 
action, ezetimibe may reduce the percentage of sdLDL parti-
cles in patients with high TG levels [175, 176]. In a meta-
analysis of 5, 039 patients, ezetimibe significantly increased 
HDL-C levels and lowered TG levels [174]. Ezetimibe also 
exerts anti-inflammatory effects and a recent meta-analysis 
reported an additional 10% reduction in hsCRP levels when 
this agent was added to statins [173, 177]. Ezetimibe also 
appears to improve renal function [178-180]. In patients with 
T2DM or MetS, statin-ezetimibe combination lowered LDL-
C, TG, non-HDL-C and hsCRP levels and increased HDL-C 
levels more than statin monotherapy [181, 182]. In other 
studies in patients with MetS, simvastatin 80 mg/day in-
duced similar or greater improvements in postprandial li-
paemia compared with ezetimibe plus simvastatin 10 mg/day 
[183, 184]. However, only the combination prevented fat-
load-induced endothelial dysfunction [184]. Endothelial dys-
function appears to be present in patients with MetS [185]. 
7. Ezetimibe-Fibrate Combination Treatment 
  In dyslipidaemic patients with IR who are intolerant to 
statins, ezetimibe-fibrate combination is a reasonable treat-
ment option [186]. This strategy induces changes reflecting 
the combined effects of fenofibrate in reducing TG-rich 
lipoproteins and promoting a shift in the LDL particle distri-
bution profile toward larger, more buoyant particles and of 
ezetimibe in promoting reductions in cholesterol mass across 
the apoB particle spectrum [187]. Thus, it seams that this co-
administration provides a complementary therapy that im-
proves the atherogenic lipid profile of patients with mixed 
hyperlipidaemia or postprandial hyperlipidaemia [186-188]. 
CONCLUSIONS 
  In order to address the residual CVD risk and optimize 
the lipid profile in patients with IR (obesity, MetS and 
T2DM), it appears that, in addition to targeting the LDL-C 
(to below 2.6 mmol/l <100 mg/dl), there is a potential benefit 
from raising the HDL-C level and lowering TG-rich particles 
[(non-HDL-C levels to below 3.4 mmol/l (130 mg/dl)] in 
patients without CAD. In those with IR and CAD we have to 
aim at lower targets [LDL-C level < 1.8 mmol/l (70 mg/dl) 
and non-HDL-C level < 2.6 mmol/l (100 mg/dl)] [113]. 
ApoB might be more predictive of CVD events than LDL-C, 
at least in patients with higher cardiometabolic risk [189]. 
Elevated apoB levels might also play a role in the increased 
vascular risk in patients with MetS who belong to other eth-
nic groups (e.g. South Asians) [190]. The effects of lifestyle 
modification and drug treatment on LDL particle size [191, 
192], HDL particle size [99] and reverse cholesterol trans-
port [193, 194] appear to play an important role in reducing 
residual CVD risk [195]. 
  To address the challenge posed by the global epidemic of 
obesity, MetS and T2DM, we need to emphasize education 
and communication to increase awareness of the important 
contribution of IR-associated atherogenic dyslipidaemia to 
the residual vascular risk. Lifestyle modification is an impor-
tant, effective and underutilised first step in reducing this 
risk. Pharmacological interventions aiming at achievement 
of all lipid targets is also likely to be required, with a combi-
nation of statin with other hypolipidaemic agents being the 
treatment of choice in most cases. 
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ABBREVIATIONS 
BMI =  Body  mass  index 
BP =  Blood  pressure 
CAD  =  Coronary artery disease 
CETP  =  Cholesteryl ester transfer protein 
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CVD =  Cardiovascular  disease 
HDL-C  =  High density lipoprotein cholesterol 
HL =  Hepatic  lipase 
HOMA  =  Homeostasis model assessment index 
hsCRP  =  High sensitivity C-reactive protein 
IR =  Insulin  resistance 
LpL =  Lipoprotein  lipase 
Lp-PLA(2)  =  Lipoprotein-associated phospholipase A2 
LDL-C  =  Low density lipoprotein cholesterol 
MetS =  Metabolic  syndrome 
PUFA  =  Polyunsaturated fatty acids 
T2DM  =  Type 2 diabetes mellitus 
VLDL-C  =  Very low density lipoprotein cholesterol 
WAT =  White  adipose  tissue 
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